MX388717B - Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. - Google Patents

Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.

Info

Publication number
MX388717B
MX388717B MX2018015120A MX2018015120A MX388717B MX 388717 B MX388717 B MX 388717B MX 2018015120 A MX2018015120 A MX 2018015120A MX 2018015120 A MX2018015120 A MX 2018015120A MX 388717 B MX388717 B MX 388717B
Authority
MX
Mexico
Prior art keywords
difluoroacetamide
dioxopiperidin
oxoisoindolin
chlorophenyl
methyl
Prior art date
Application number
MX2018015120A
Other languages
English (en)
Spanish (es)
Other versions
MX2018015120A (es
Inventor
Antonia Lopez-Girona
Gang Lu
Irit Rappley
Kyle Macbeth
Michael Pourdehnad
Paul Hollenbach
Soraya Carrancio
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2018015120A publication Critical patent/MX2018015120A/es
Publication of MX388717B publication Critical patent/MX388717B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018015120A 2016-06-06 2017-06-05 Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. MX388717B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346344P 2016-06-06 2016-06-06
PCT/US2017/035892 WO2017214014A1 (en) 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Publications (2)

Publication Number Publication Date
MX2018015120A MX2018015120A (es) 2019-04-15
MX388717B true MX388717B (es) 2025-03-20

Family

ID=60482040

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015120A MX388717B (es) 2016-06-06 2017-06-05 Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.

Country Status (15)

Country Link
US (4) US10245258B2 (OSRAM)
EP (1) EP3463358A4 (OSRAM)
JP (1) JP7163281B2 (OSRAM)
KR (1) KR20190015300A (OSRAM)
CN (2) CN109414436A (OSRAM)
AU (2) AU2017278114B2 (OSRAM)
BR (1) BR112018075206A2 (OSRAM)
CA (1) CA3026396A1 (OSRAM)
CL (1) CL2018003499A1 (OSRAM)
EA (1) EA201892746A1 (OSRAM)
IL (1) IL262565B (OSRAM)
MX (1) MX388717B (OSRAM)
SG (1) SG11201809501PA (OSRAM)
WO (1) WO2017214014A1 (OSRAM)
ZA (1) ZA201807105B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
MX390772B (es) * 2016-01-08 2025-03-21 Celgene Corp Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
US11535603B1 (en) 2016-09-30 2022-12-27 Deuterx, Llc Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same
PL3689868T3 (pl) 2016-12-01 2024-03-11 Arvinas Operations, Inc. Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
CA3125189A1 (en) * 2018-12-31 2020-07-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
CA3154923A1 (en) 2019-10-21 2021-04-29 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
WO2021091946A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
CN114761004A (zh) 2019-12-06 2022-07-15 细胞基因公司 用于制备2-(4-氯苯基)-n-((2-(2，6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2，2-二氟乙酰胺的方法
BR112022018515A2 (pt) * 2020-03-16 2022-11-16 Celgene Corp Terapia de combinação para leucemia mieloide aguda
BR112023004656A2 (pt) * 2020-09-14 2023-05-09 Arvinas Operations Inc Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
MX2023003114A (es) 2020-09-23 2023-03-23 St Jude Childrens Res Hospital Inc Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-i l)arilsulfonamida sustituidos como moduladores de la proteina cereblon.
KR20240066906A (ko) * 2022-11-08 2024-05-16 주식회사 온코드바이오 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050044655A (ko) * 2001-12-03 2005-05-12 노바세아, 인크. 활성 비타민 ｄ 화합물을 함유하는 약제학적 조성물
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20090175869A1 (en) 2007-05-31 2009-07-09 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
ATE505194T1 (de) 2009-05-20 2011-04-15 Hybrigenics Sa Neue therapeutische verwendungen von inecalcitol
EA201490911A1 (ru) 2011-11-01 2014-09-30 Селджин Корпорейшн Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
US20160303158A1 (en) * 2013-12-05 2016-10-20 Hoffmann-La Roche Inc. Novel combination treatment for acute myeloid leukemia (aml)
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US10189808B2 (en) 2016-01-08 2019-01-29 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
AR107321A1 (es) 2016-01-08 2018-04-18 Celgene Corp Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
CA3010797C (en) 2016-01-08 2024-01-02 Celgene Corporation Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Also Published As

Publication number Publication date
AU2017278114A1 (en) 2018-11-29
US20210154182A1 (en) 2021-05-27
BR112018075206A2 (pt) 2019-03-19
CN109414436A (zh) 2019-03-01
US20230158009A1 (en) 2023-05-25
IL262565A (en) 2018-12-31
AU2017278114B2 (en) 2023-01-12
IL262565B (en) 2022-08-01
US10245258B2 (en) 2019-04-02
MX2018015120A (es) 2019-04-15
WO2017214014A1 (en) 2017-12-14
KR20190015300A (ko) 2019-02-13
AU2023202159A1 (en) 2023-05-04
CL2018003499A1 (es) 2019-03-15
SG11201809501PA (en) 2018-12-28
EP3463358A1 (en) 2019-04-10
EP3463358A4 (en) 2020-07-22
US20190175573A1 (en) 2019-06-13
CA3026396A1 (en) 2017-12-14
JP7163281B2 (ja) 2022-10-31
US20170348298A1 (en) 2017-12-07
CN115282149A (zh) 2022-11-04
EA201892746A1 (ru) 2019-06-28
ZA201807105B (en) 2020-01-29
US11590117B2 (en) 2023-02-28
JP2019517587A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
MX388717B (es) Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
ZA202202097B (en) Amino pyrimidine ssao inhibitors
MX2022001410A (es) Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
EA033689B9 (ru) Ингибиторы g12c kras
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
EA201590345A1 (ru) Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
RU2016141934A (ru) Ингибиторы циклин-зависимой киназы 7 (cdk7)
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
MX2022011523A (es) Terapia combinada para leucemia mielógena aguda.
MX2017000366A (es) Terapia de combinacion para el cancer.
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
MX2022005371A (es) Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperi din-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2018006779A (es) Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona.
ECSP18023544A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
MX2023013011A (es) Métodos de tratamiento con n-((r)-1-(3-cloropiridin-2-il)- 2,2,2-trifluoroetil)-2-((s)-2,6-dioxopiperidin-3-il)-1- oxoisoindolin-5-carboxamida.
EA202090176A1 (ru) Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов
MX388249B (es) Composición farmacéutica de desloratadina para ser administrada por vía oral, para el tratamiento de enfermedades relacionadas con la histamina.